Colony-stimulating factors for chemotherapy-related febrile neutropenia are associated with improved prognosis in adult acute lymphoblastic leukemia

Ye,Shi‑Guang; Ding,Yi; Li,Liang; Yang,Meng; Zhang,Wen‑Jun; Liang,Ai‑Bin

doi:10.3892/mco.2015.527

Colony-stimulating factors for chemotherapy-related febrile neutropenia are associated with improved prognosis in adult acute lymphoblastic leukemia

Authors:
- Shi‑Guang Ye
- Yi Ding
- Liang Li
- Meng Yang
- Wen‑Jun Zhang
- Ai‑Bin Liang
View Affiliations

Affiliations: Department of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200092, P.R. China
Published online on: March 6, 2015 https://doi.org/10.3892/mco.2015.527
Pages: 730-736

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colony‑stimulating factors (CSF) have been widely used to prevent febrile neutropenia associated with chemotherapy. Due to the high intensity of chemotherapy in acute lymphoblastic leukemia (ALL), CSF as a crucial component of supportive care has played a significant role in the therapy. However, the effectiveness of CSF in treatment has not been identified by large clinical trials until now. The aim of the present study was to evaluate the effect of CSF on the long‑term outcome of adult ALL patients. A comprehensive search strategy has been conducted, which covered the Cochrane Central Register of Controlled Trials, PubMed and Web of Science. The result includes seven randomized controlled trials containing a total of 753 patients. The administration of CSF significantly reduced the mortality at the end of the follow‑up (RR, 0.85; 95% CI, 0.75‑0.95), the mortality at day 30 (RR, 0.41; 95% CI, 0.23‑0.74) and the number of patients with infection or severe infections (RR, 0.8; 95% CI, 0.7‑0.9 and RR, 0.48; 95% CI, 0.3‑0.75). The addition of CSF also marginally increased the number of patients achieving CR (RR, 1.14; 95% CI, 1.05‑1.23). The use of CSF also shortened the duration of neutropenia (median days, 8‑17 to 12.5‑24). In conclusion, CSFs can be administered to ALL patients during myelosuppressive chemotherapy, particularly in the induction phase.

View Figures

View References

1	Jabbour EJ, Faderl S and Kantarjian HM: Adult acute lymphoblastic leukemia. Mayo Clinic Proc. 80:1517–1527. 2005. View Article : Google Scholar
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
3	Hiroto Inaba MG and Charles G Mullighan: Acute lymphoblastic leukaemia. Lancet. 381:1943–1955. 2013. View Article : Google Scholar : PubMed/NCBI
4	Esparza SD and Sakamoto KM: Topics in pediatric leukemia-acute lymphoblastic leukemia. Med Gen Med. 7:232005.
5	Pui CH and Evans WE: Acute lymphoblastic leukemia. N Engl J Med. 339:605–615. 1998. View Article : Google Scholar : PubMed/NCBI
6	Pui CH, Pei D, Sandlund JT, et al: Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B and 14 for childhood acute lymphoblastic leukemia. Leukemia. 24:371–382. 2010. View Article : Google Scholar : PubMed/NCBI
7	Gaynon PS, Angiolillo AL, Carroll WL, et al: Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: a Children's Oncology Group Report. Leukemia. 24:285–297. 2010. View Article : Google Scholar : PubMed/NCBI
8	Linker C, Damon L, Ries C and Navarro W: Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 20:2464–2471. 2002. View Article : Google Scholar : PubMed/NCBI
9	Kantarjian H, Thomas D, O'Brien S, et al: Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 101:2788–2801. 2004. View Article : Google Scholar : PubMed/NCBI
10	Rowe JM, Buck G, Burnett AK, et al: Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 106:3760–3767. 2005. View Article : Google Scholar : PubMed/NCBI
11	Bassan R and Hoelzer D: Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 29:532–543. 2011. View Article : Google Scholar : PubMed/NCBI
12	Annino L, Vegna ML, Camera A, et al: Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 99:863–871. 2002. View Article : Google Scholar : PubMed/NCBI
13	Larson RA, Dodge RK, Burns CP, et al: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 85:2025–2037. 1995.PubMed/NCBI
14	Takeuchi J, Kyo T, Naito K, et al: Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia. 16:1259–1266. 2002. View Article : Google Scholar : PubMed/NCBI
15	Thomas X, Boiron JM, Huguet F, et al: Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 22:4075–4086. 2004. View Article : Google Scholar : PubMed/NCBI
16	Griffin JD: Hematopoietic growth factorsCancer: Principles and Practice of Oncology. DeVita VT Jr, Hellman S and Rosenburg SA: 1. 6th. Lippincott Williams & Wilkins; Philadelphia, PA: pp. 2798–2809. 2001
17	Petros WP: Colony-stimulating factorsCancer Chemotherapy and Biotherapy: Principles and Practice. Chabner BA and Longo DL: 5th. Lippincott Williams & Wilkins; Philadelphia, PA: pp. 357–392. 2001
18	Ozer H, Armitage JO, Bennett CL, et al: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 18:3558–3585. 2000.PubMed/NCBI
19	The Cochrane Collaboration: Review Manager (RevMan) 5.2. http://tech.cochrane.org/revman/downloadAccessed. December 252013.
20	Geissler K, Koller E, Hubmann E, et al: Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia-a randomized phase-III study. Blood. 90:590–596. 1997.PubMed/NCBI
21	Hallbook H, Bjorkholm M, Hagglund H and Smedmyr B: Does granulocyte colony-stimulating factor improve long-term outcome in adult acute lymphoblastic leukemia? Leuk Lymphoma. 50:1872–1874. 2009. View Article : Google Scholar : PubMed/NCBI
22	Holowiecki J, Giebel S, Krzemien S, et al: G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: a randomized multicenter study. Leuk Lymphoma. 43:315–325. 2002. View Article : Google Scholar : PubMed/NCBI
23	Ifrah N, Witz F, Jouet JP, et al: Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. GOELAMS Group. Cancer. 86:1496–1505. 1999. View Article : Google Scholar : PubMed/NCBI
24	Larson RA, Dodge RK, Linker CA, et al: A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 92:1556–1564. 1998.PubMed/NCBI
25	Ottmann OG, Hoelzer D, Gracien E, et al: Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood. 86:444–450. 1995.PubMed/NCBI
26	Thomas X, Boiron JM, Huguet F, et al: Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study. Hematol J. 5:384–394. 2004. View Article : Google Scholar : PubMed/NCBI
27	Bohlius J, Herbst C, Reiser M, Schwarzer G and Engert A: Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev: CD003189. 2008. View Article : Google Scholar
28	Clark OA, Lyman G, Castro AA, Clark LG and Djulbegovic B: Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev: CD003039. 2003.
29	Renner P, Milazzo S, Liu JP, Zwahlen M, Birkmann J and Horneber M: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Cochrane Database Syst Rev: CD007913. 2012. View Article : Google Scholar
30	Gurion R, Belnik-Plitman Y, Gafter-Gvili A, et al: Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev: CD008238. 2011. View Article : Google Scholar
31	Giebel S, Thomas X, Hallbook H, et al: The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: a joint analysis of five randomised trials on behalf of the EWALL. Eur J Cancer. 48:360–367. 2012. View Article : Google Scholar : PubMed/NCBI
32	Inukai T, Sugita K, Iijima K, et al: Leukemic cells with 11q23 translocations express granulocyte colony-stimulating factor (G-CSF) receptor and their proliferation is stimulated with G-CSF. Leukemia. 12:382–389. 1998. View Article : Google Scholar : PubMed/NCBI
33	Benko I, Kovacs P, Szegedi I, et al: Effect of myelopoietic and pleiotropic cytokines on colony formation by blast cells of children with acute lymphoblastic leukemia. Naunyn-Schmiedeberg's Arch Pharmacol. 363:499–508. 2001. View Article : Google Scholar
34	Gattei V, Aldinucci D, Attadia V, et al: Human granulocyte-macrophage colony-stimulating factor supports the clonogenic growth of B-lineage acute lymphoblastic leukemias expressing myeloid antigens. Cytokines Cell Mol Ther. 3:141–151. 1997.PubMed/NCBI
35	Lexchin J, Bero LA, Djulbegovic B and Clark O: Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 326:1167–1170. 2003. View Article : Google Scholar : PubMed/NCBI